Cortexyme Inc (the company was transformed to Quince Therapeutics (QNCX)) (CRTX) Event May 20, 2022, 12:15 UTC 19 1 comments (99% Neutral) CORTEXYME, INC. (CRTX) Announces Executive Departure Comment Full text
Sesen Bio Inc (merger with a company Carisma Therapeutics Inc (NASDAQ:CARM)) (SESN) Event May 20, 2022, 12:00 UTC 20 1 comments (19% Negative) SESEN BIO, INC. (SESN) Announces Regulatory Update Comment Full text
Amarin Corporation Plc (AMRN) Event May 20, 2022, 11:47 UTC 19 1 comments (99% Neutral) AMARIN CORP PLC\UK (AMRN) Announces Business Combination Comment Full text
Y-mAbs Therapeutics Inc (YMAB) Event May 19, 2022, 20:35 UTC 19 1 comments (99% Neutral) Y-MABS THERAPEUTICS, INC. (YMAB) Announces New Board Appointment Comment Full text
Personalis Inc (PSNL) Event May 19, 2022, 20:30 UTC 19 1 comments (99% Neutral) Personalis, Inc. (PSNL) Announces Regulatory Update Comment Full text
Atara Biotherapeutics Inc (ATRA) Event May 19, 2022, 20:05 UTC 19 1 comments (19% Negative) Atara Biotherapeutics, Inc. (ATRA) Announces Clinical Trial Timeline Adjustment Comment Full text
Replimune Group Inc (REPL) Event May 19, 2022, 12:10 UTC 20 1 comments (75% Positive) REPLIMUNE GROUP, INC. (REPL) Announces Enrollment Update for results Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment Comment Full text
Epizyme Inc Ipsen (the company became a subdivision of the company IPSEN (Euronext: IPN; ADR: IPSEY)) (EPZM) Event May 19, 2022, 11:57 UTC 19 1 comments (99% Neutral) EPIZYME, INC. (EPZM) Announces Executive Changes Comment Full text
ObsEva SA (company was delisted NASDAQ) (OBSV) Event May 19, 2022, 11:05 UTC 18 1 comments (99% Neutral) ObsEva SA (company was delisted NASDAQ) (OBSV) Announces 2022 Annual General Meeting Comment Full text
Instil Bio Inc (TIL) Event May 18, 2022, 21:03 UTC 19 1 comments (10% Negative) Instil Bio, Inc. (TIL) Announces Delay in patients Trials for cancer Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Efficacy Assessment Comment Full text